Close

Barclays Keeps 'Overweight' on Alexion Pharmaceuticals (ALXN); Beat & Raise with Three Potential Catalysts Ahead

July 26, 2012 5:35 PM EDT Send to a Friend
Barclays maintains an 'Overweight' on Alexion Pharmaceuticals (NASDAQ: ALXN) price target of $112.00 (from $104.00).

Analyst, Ying Huang calls ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login